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Abstract
Introduction: Neurological immune-related adverse events are a rare but potentially deadly
complication after immune checkpoint inhibitor (ICI) treatment. As multiple sclerosis (MS) is an
immune mediated disease it is unknown how ICI treatment may affect outcomes.
Methods: We analyzed the United States Food and Drug Administration (FDA) Adverse Event
Reporting System (FAERS) database for pembrolizumab, atezolizumab, nivolumab, ipilimumab,
avelumab, and durvalumab two years prior their FDA approval until December 31, 2017, to
include all cases with confirmed diagnosis/relapse of MS. We also included cases reported in the
literature and a patient from our institution.
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Results: We identified 14 cases of MS with median age of presentation of 52 years. Indications
for ICI included melanoma in 7 (36.36%) cases, non-small cell lung carcinoma in 2 (18.18%)
cases, 1 case (9.09%) each of pleural mesothelioma, renal cell carcinoma, and colorectal cancer,
and unreported in 2 (18.18%) cases. History of MS was confirmed in 8 (57.1%) cases. Median
time to beginning of symptoms was 29 days with rapid disease progression; 2 patients died due to
their relapse. Median time for symptom resolution was 8 weeks. Outcomes did not vary by
comparing CTLA-4 and PD-1/PD-L1 inhibitors.
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Conclusions: Reported MS relapses after ICI are rare but the adverse events described include
rapid neurologic progression and death. Larger and prospective studies are warranted to assess
disability and long-term outcomes and outweigh the risks of starting immunotherapy in patients
with MS.
Keywords
1-Multiple sclerosis; 2-immune checkpoint inhibitors; 3-immune related adverse events

INTRODUCTION
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Immune checkpoint inhibitors (ICI) include CTLA-4 and PD-1/PD-L1 inhibitors and have
recently become the standard of care for a growing list of cancers, including melanoma, nonsmall cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer,
urothelial carcinoma, and microsatellite instability-high solid tumors[2, 4, 5, 9, 16, 24, 28,
34, 35]. Immunotherapies differ from conventional chemotherapy as they are not directly
cytotoxic, but are designed to engage the immune system to generate antitumor activity[13].
CTLA-4 and PD-1/PD-L1 are ligands to the B7 costimulatory pathway that mediate T-cell
inhibition[19]. Due to their mechanisms of action, ICI have been associated with a unique
spectrum of immune related adverse events (irAEs) by deregulating the response of T cells
to antigens presented by normal cells. A possibility exists for immune mediated diseases,
such as multiple sclerosis (MS), to be triggered or significantly aggravated with the use of
these medications[6, 10]. However, knowledge on the neurological irAEs is still insufficient
due to the novelty of these drugs.
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MS affects more than 400,000 people in the United States, presenting with an array of
clinical presentations that include vision loss, limb weakness, sensory abnormalities, or
ataxia[1]. Several studies support an inflammatory patient-dependent immune-mediated
component for MS[27, 43], with genetic and environmental risk factors identified[3], and a
T-cell mediated pathogenesis mechanistically similar to ICI[22, 39].
Neurological complaints are one of the most common reasons for hospital admission in
cancer patients[31]. Severe neurological irAEs with ICI therapy have been reported in less
than 1% of patients[23, 40, 42, 45]. The majority of neurological irAEs manifest
predominantly as peripheral neuropathy and are generally associated with a benign course[8,
25]. MS is the most common cause of permanent disability in young adults[30, 33], with
limited response to treatment. Future functional impairment is a major concern if a relapse
develops during ICI therapy, more so than with other neurological irAEs.
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No study has focused on the outcomes of MS patients after ICI therapy, and with an
increasing approval of ICI use safety in these patients will be an important clinical question.
Due to the heterogeneity of MS, response after ICI may be unpredictable. We analyzed the
outcomes of documented cases of MS relapse after treatment with ICI in a comprehensive
analysis of the available published literature, the Food and Drug Administration (FDA)
Adverse Event Reporting System (FAERS) database, and our institutional experience.
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METHODS
We present one case from our institution, a review of the published literature, and the
FAERS database for patients who developed MS relapse during cancer therapy with ICI.
FAERS data was provided by the FDA upon request.
Search strategy
Institutional—We performed a retrospective analysis of cancer patients that received at
least one cycle of pembrolizumab, atezolizumab, nivolumab, ipilimumab, avelumab, and/or
durvalumab during any part of their cancer treatment and that had a history of MS that
developed symptoms during or after their therapy with ICI. Only 1 patient was identified
from this search.
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FAERS—We analyzed the FAERS database for pembrolizumab, atezolizumab, nivolumab,
ipilimumab, avelumab, and durvalumab from 2 years before their FDA approval until
December 31, 2017, to include all cases with confirmed diagnosis of MS. After case
identification, detailed reports were requested to the FDA and information is presented as
available in those reports. Multiple reports that described the same patient were grouped
together.
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FAERS is an international database maintained by the FDA that collects de-identified
information on adverse event reports, medication error, and product quality complaints.
Reports are limited to the information disclosed by the reporter, which includes health care
providers, drug manufacturers, and consumers. Information included in these reports details
drug exposure, disease indications, and clinical outcomes[36, 37]. FAERS is a reliable
source of information that has been used extensively by researchers and our group in several
areas to describe post-marketing surveillance of medications[15]. It provides a unique
opportunity to assess cases globally with detailed reports of their event.
Based on FDA regulations, outcomes are reported in the following categories: congenital
anomaly/birth defect, death, disability, hospitalization, life threatening, other serious
important medical event, and required intervention to prevent permanent impairment/
damage. OT is defined as an outcome that does not fit other categories, but may jeopardize
patients requiring medical or surgical intervention to prevent one of the other outcomes.
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Literature—We performed a systematic review of the literature using the PubMed
database. We searched for all published literature regarding MS and nivolumab, ipilimumab,
atezolizumab, pembrolizumab, avelumab, or durvalumab use until April 11, 2018. Our
search included combinations of the keyword “multiple sclerosis” with “nivolumab”,
“ipilimumab”, “atezolizumab”, “pembrolizumab”, “durvalumab”, and “avelumab”. Two
researchers performed this search independently for internal validity. Only three articles
were found[6, 10, 11], and were reviewed in full-text form. No language, time, age, or date
filters were included in our search.

Clin Transl Oncol. Author manuscript; available in PMC 2020 October 01.
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Categorical variables are presented in frequency and percentages. Continuous variables are
presented with medians. Results were compared using Fisher’s exact tests and Wilcoxon
Rank Sum tests presented as p-values. The level of statistical significance was set at 0.05 for
all tests conducted, and all analyses were performed with SPSS software version 23.

RESULTS
Our analysis of FAERS captured 42,529 adverse events with the use of ICI with 13 cases
identified with MS. In the published literature our search identified three cases, but they
were matched to cases in FAERS, as they contained identical clinical and treatment history,
and were not counted as additional cases. We present an additional case from our practice
further below.
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The median age of presentation for MS cases identified was 52.5 years. ICI were used in the
following indications (cancer type): melanoma (n=7), non-small cell lung carcinoma in
(n=2), pleural mesothelioma (n=1), renal cell carcinoma (n=1), and colo-rectal cancer (n=1).
The indication was not reported in 2 patients.
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The ICI with higher number of reported cases of MS was nivolumab (n=9), followed by
ipilimumab (n=5), pembrolizumab (n=2), and atezolizumab (n=1). No cases were attributed
to durvalumab or avelumab. We found no differences while comparing agents or mechanism
of action (PD-1 axis versus CTLA-4 inhibitors) between demographics or outcomes
variables. History of MS was confirmed in 8 patients. One patient had a history of vitiligo,
otherwise an autoimmune disorder history was negative or unknown. All of the patients had
diagnosis of metastatic disease. Previous cancer therapy is largely unknown, but the cases
that reported it received several courses of chemotherapy, surgery, and radiation prior to
beginning immunotherapy. MS treatment was reported in 4 patients, 3 of which were
previously receiving glatiramer acetate, and 1 patient was receiving interferon-beta. Of these
patients, three were not receiving MS treatment while on ICI. The reason was to avoid
possible interference with the mechanism of action (2 patients), withholding therapy before
starting ICI, and because the diagnosis of MS was not clear before ICI therapy (1 patient).
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Clinical presentation varied from paresthesias, vision changes, weakness, and altered mental
status (table 2). A detailed description of the clinical presentation of case 10, 11, and 14 is
available in the literature[6, 10, 11], and case 5 was presented at the Society for Neuro
Oncology Annual Meeting in 2016[12]. The basis for the diagnosis of MS was reported in 8
cases and was based on combination of clinical presentation, MRI brain studies (8 cases),
biopsy (2 cases), and cerebrospinal fluid analyses (2 cases). Median time to symptom onset
was 29 (12–120) days, with a median of 2 cycles to onset. Patients receiving CTLA-4
inhibitors had a numerically higher median time to onset of event, and number of cycles
compared to PD-1/PD-L1 inhibitors, but was not statistically significant (Table 1). In all
cases, the drug was discontinued when the clinical diagnosis of MS was clear. One patient
was re-treated with ipilimumab after presenting mild symptoms of MS relapse, due to the
beneficial cancer response. His MS symptoms significantly worsened following retreatment
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and his re-trial was discontinued. In two other cases, the course of MS relapse was
particularly serious, with rapid progression and poor response to MS therapy.
Therapy for MS relapse was provided for 5 patients who received IV corticosteroids.
Patients were not reported to have received any form of immunotherapy prior to or during
immune checkpoint inhibitor administration. Symptom resolution was reported in 5 patients,
with 3 patients presenting MS progression and significant disability, including 2 patients
who died from their disease. Overall median duration of event as 56 (21–112) days. Median
symptom duration was 4 weeks for PD axis inhibitors, with a trend to longer duration in
CTLA-4 inhibitors that was not statistically significant (12 weeks compared to 4 weeks,
p=0.700) (Table 2). All cases presented with other serious adverse events and 4 patients
required hospitalization.
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Case Report
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A 49-year-old woman with a history of relapsing remitting MS since 2003, and metastatic
colonic adenocarcinoma since January 2015. She received off label use of atezolizumab with
cobimetinib, a reversible inhibitor of mitogen-activated protein kinase/extracellular signal
regulated kinase (MEK), in August 2016. Two weeks following single treatment she
presented to the ED with a 3-day history of persistent fever and progressing confusion. She
was admitted and underwent workup including brain and body imaging, laboratory tests, and
cerebrospinal fluid (CSF) analysis. The laboratory workup was negative except for mild
residual neutropenia and hyponatremia, and an increased total protein in CSF. An infectious
cause was ruled out. Brain MRI on September 2016 demonstrated nonspecific T2
hyperintense lesions within the subcortical, deep, and periventricular white matter. No
leptomeningeal enhancement was evident in the images. A presumptive diagnosis of MS
relapse was made based on her history.
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The patient’s MS had been treated regularly with glatiramer acetate since 2009, with her last
MS relapse in 2014. She was using glatiramer during her treatment with atezolizumab. Her
cancer had been treated aggressively with multiple lines of chemotherapy, and surgical
procedures (right colectomy, liver sectionectomy, and right hepatic artery
radioembolization). Chemotherapy included FOLFOXIRI [5-fluorouracil (5-FU)/leucovorin,
oxaliplatin, irinotecan] plus bevacizumab, 5-FU and bevacizumab, trifluridine and tipiracil,
FOLFIRI (folinic acid, 5-FU, and irinotecan) plus bevacizumab, and regorafenib. The MS
relapse being attributable to atezolizumab therapy was deemed probable based on the
Naranjo Algorithm for Adverse Drug Reaction Probability Scale (Score=6)[29]. Her
neurological status continued to deteriorate, showing no response to high-dose
corticosteroids or supportive measures. Follow up imaging demonstrated a decreased size of
liver metastases, but suspected disease progression versus pseudoprogression in the chest.
Therapy was withheld due to her clinical status and she passed away a month after her first
dose of atezolizumab.

DISCUSSION
Immune checkpoint inhibitors are thought to induce epitope spreading and a broader T cell
response[22, 39], that may trigger immune-mediated syndromes. Previous analyses have
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demonstrated similar proliferation rates and pro-inflammatory cytokine production of
myelin-reactive CD4+ T cells from ipilimumab treated patients, comparable to patients with
MS[6]. In addition, in patients with a history of kidney transplantation that received
ipilimumab, T-cell mediated graft rejection has been described[44].
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The outcomes of patients presenting with neurological irAEs are thought to be favorable[7,
32], however there are few severe reactions described with severe organ failure leading to
death[7, 8, 46]. Out of the fourteen cases, eight had a reported history of MS. The frequency
of clinically isolated or radiographically isolated syndrome in patients that received
immunotherapy is difficult to assess and would require a high level of suspicion in
prospective studies. All of the patients in our analysis presented rapid disease progression
requiring medical intervention, and two patients died from their MS relapse. Imaging, or
pathological patterns, biopsy, or autopsy material was not available for our review, and is a
limitation to FAERS data analysis.
The time to event for irAE remain an active area of investigation and may range from weeks
to months[32]. Single center experiences and retrospective reviews describe a range of
neurological irAEs that includes headaches, neuropathies, meningitis, and myasthenic
syndromes[7, 18]. This literature describes a median time to event of 6–13 weeks after
therapy, with an incidence as high as 12% for reported neurological irAEs for combinatorial
use of anti-PD1 and anti-CTLA-4 inhibitors[7, 14, 18].
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The median of 29 days in our study, with few cases successfully responding to symptomatic
treatment, suggests a rapid and aggressive reaction. Patients in our analysis had a median
age of 52.5 years, younger than described for other neurological irAEs (56–71 years)[7, 18].
No clear association between ICI agent and neurological syndromes have been described to
date[7], and in our analysis no demographic or outcome variables were found to be different
between ICI agents. We believe the higher number of cases of nivolumab, and the higher
number of cases with melanoma are related to earlier FDA approval, rather than agent or
disease specific syndrome.
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Specific cancer types may have a higher predisposition of developing neurological AEs.
Neuropathies are more commonly associated with ANNA-1 antibodies, that are seen
primarily in small cell lung cancer, breast cancer, and renal cancer[41]. The close temporal
relationship of immune checkpoint inhibitors administration to the development of
symptoms and documented MRI activity provide basis to support causation of immune
checkpoint inhibitors to the MS relapse. Similar basis is used for other drugs related adverse
events and is validated by the Naranjo Algorithm for Adverse Drug Reaction Probability
Scale[29].
Eight patients had a history of MS in our analysis, of which 5 reported symptom resolution.
A history of autoimmune disorders as a contraindication for ICI therapy is under debate, as
some patients may still benefit from immune-based cancer therapies. Yet, it is expected that
around 30% will either experience a flare of their disease or a new immunological event,
generally with mild severity[17, 26]. Limited evidence after solid organ transplantation
suggests ICI should be used with caution, and may result in graft loss and life-threatening
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events[20, 21]. However, the reduction of immunosuppression has been questioned as the
cause of graft loss[44]. Some patients had stopped MS therapy at the time they received
immunotherapy. Nonetheless, the effect of immunomodulation of MS is not as predictable as
immunosuppression after transplantation. Severe, life-threatening immune-based syndromes
have been previously described after adjuvant exposure (vaccination, systemic viral
infection) and ICI may trigger similar presentations[38].
Disease presentation was variable between cases, but was particularly severe in 3 cases, one
of which was seen in our institution. Our patient presented a clinical syndrome resembling
autoimmune encephalitis, with decreased level of consciousness and rapid progression.
Immune activation cascade may differ from patient to patient[41], but much is still unknown
on risk factors for developing neurological irAE. As the use of ICI increases, the number of
patients presenting these reactions will increase.
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Retrospective cohorts have demonstrated an adequate cancer response in patients that
present irAEs[17]. Only two of our cohort were re-exposed or continued treatment.
Interestingly, the majority of cases continued to manifest MS symptoms long after stopping
therapy (Figure 1), likely related to the long half-life of ICI[7], and a prolonged and
sustained immune response. A history of multiple rounds of cancer treatment, as was the
case in the majority of these patients, may increase the risk and severity of neurotoxicities.
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Some of the limitations of our study include the lack of detailed MS follow up, disability
measures, and long outcome data. Reporting bias is a significant limitation of our sample, as
cases with worst outcomes were more likely to be reported to the FDA. Larger analyses
might confirm outcome differences between CTLA-4 inhibitors and PD-1 axis inhibitors in
terms of MS relapse. Our analysis demonstrates ICI therapy in patients with MS may be
associated with rapid worsening neurological condition and death. Future longitudinal
studies to assess worsening neurologic function in patients with MS relapse after ICI therapy
would provide information regarding prognosis and help outweigh the risks of ICI in these
patients.

Funding:
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Figure 1.

Author Manuscript

Swimmers plot for duration of ICI therapy and MS symptoms. The orange line depicts the
time since starting an ICI to the time that MS symptoms began. The blue line depicts the
duration of symptoms.
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Table 1.

Author Manuscript

Overall demographics and characteristics by patients (TTE: Time to event)

Author Manuscript

Case

Age

Gender

Indication

ICI

Hx
of
MS

TTE

CTE

Total
Cycles

Outcome

Resolution

Duration

1

58

F

Melanoma

Pembrolizumab

Yes

3 wks

1

3

OT

Yes

NR

2

NR

M

Pleural
mesothelioma

Pembrolizumab

NR

NR

NR

NR

HO, OT

No

3 mo

3

50

F

Melanoma

Nivolumab

Yes

NR

NR

NR

OT

NR

NR

4

63

F

NSCLC

Nivolumab

NR

2 mo

2

2

OT

NR

NR

5

43

F

NSCLC

Nivolumab

Yes

12 d

1

1

HO, OT

Yes

1 mo

6

NR

NR

NR

Nivolumab

NR

NR

NR

NR

OT

NR

NR

7

NR

NR

NR

Nivolumab

NR

NR

2

2

OT

NR

NR

8

45

M

RCC

Nivolumab

No

NR

NR

NR

OT

NR

NR

9

49

F

Colorectal

Atezolizumab

Yes

2 wks

1

1

DE, HO

No

1 mo

10

76

F

Melanoma

Ipilimumab

No

4 wks

4

4

DE

No

4 mo

11

29

M

Melanoma

Ipilimumab

Yes

4 mo

8

8

OT, HO

Yes

3 wks

12

55

M

Melanoma

Ipilimumab

Yes

2 mo

3

3

OT

Yes

NR

13

NR

M

Melanoma

Ipilimumab

Yes

NR

NR

NR

OT

NR

NR

14

56

M

Melanoma

Ipilimumab

Yes

1 mo

4

4

OT

Yes

3 mo

ICI: Immune checkpoint inhibitor; Hx: History; MS: Multiple sclerosis; TTE: Time to event; CTE: Number of cycles to event; wks: Weeks; mo:
Months; d: days
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Table 2.

Author Manuscript

Clinical phenotype descriptions as available in the reports
Patient

Clinical presentation (as described in the reports)

1

Paresthesia and decreased strength in lower and upper limbs.

3

Numbness to hand a feet and loss of bladder control.

5

Progressive diplopia, gait instability, bilateral ptosis, internuclear opthalmoplegia, and ataxic gait.

9

Fever and progressive confusion.

10

Fatigue, memory loss, and vision changes.

11

Thermhypaesthesia of both feet.

12

Left leg weakness, left arm weakness, and significant fatigue

14

Left lower extremity hemiparesis, gait dysfunction, and ataxia.

Author Manuscript
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Table 3.

Author Manuscript

Demographics and characteristics by mechanism of action of immune checkpoint inhibitor
CTLA-4 N=5

PD-1/PD-L1 N= 9

p-value

Age (years)

Median

56

46

0.762

TTE (days)

Median

30

13

0.114

Cycles TE

Median

4

1

0.111

Total cycles

Median

4

1

0.016

Duration of event (weeks)

Median

12

4

0.700

N

%

N

%

Gender

Female

1

20.0%

5

55.6%

Male

4

80.0%

2

22.2%

Not reported

0

0.0%

2

22.2%

No

1

20.0%

1

11.1%

Yes

4

80.0%

4

44.4%

Not reported

0

0.0%

4

44.4%

No

1

20.0%

1

11.1%

Yes

4

80.0%

8

88.9%

No

4

80.0%

8

88.9%

Yes

1

20.0%

1

11.1%

No

4

80.0%

6

66.7%

Yes

1

20.0%

3

33.3%

No

1

20.0%

2

22.2%

Yes

3

60.0%

2

22.2%

Not reported

1

20.0%

5

55.6%

Not reported

3

60.0%

6

66.7%

Yes

2

40.0%

3

33.3%

Author Manuscript

History of MS

OT

DE

HO

Resolution

Author Manuscript

Corticosteroids

0.236

0.301

0.604

0.604

0.545

0.513

0.622

*

p-values are from Fisher’s exact tests and Wilcoxon Rank-Sum.

TTE: Time to event; TE: To event; MS: Multiple sclerosis; OT: Other serious complication; DE: Death; HO: Hospitalization
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